Everest Organics Limited today announced the successful development of an anti-viral API ‘MOLNUPIRAVIR’ an additional COVID-19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms.
Dr. Srikakarlapudi Sirisha, Chief Executive Officer, EOL – New Product Development said that “After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment. ‘Molnupiravir’ is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid. The APl, Molnupiravir is administered orally and works by inhibiting the replication of the coronavirus inside the body. Everest is planning and preparing to be an active player in viral segment in the upcoming future.
You may also like
-
Ayurveda and Diabetes Prevention: Lifestyle Lessons from Classical Principles
-
India Examines Regulatory Reforms to Allow Global Pharmaceutical Companies to Conduct First-in-Human Clinical Trials
-
CSIR-CCMB Scientists Identify New Potential Drug Targets Against Tuberculosis Bacterium
-
Ayurveda for Healthy Metabolism: Balancing Agni, Nutrition and Daily Living
-
India Records 38% Decline in TB Mortality, Achieves 94% Treatment Success Rate
